Literature DB >> 2649288

Circulating monocyte migration inhibitory factor in serum of Graves' ophthalmopathy patients: a parameter for disease activity?

R van der Gaag1, L Broersma, M P Mourits, L Koornneef, W M Wiersinga, M P Prummel, A Berghout.   

Abstract

A factor which inhibits the random migration of monocytes in vitro was found in the serum of nearly half of Graves' ophthalmopathy patients. This factor was found in serum of only 4% of the healthy controls. When the Graves' ophthalmopathy patients were subdivided, on clinical criteria (pain, redness, swelling and impaired function), into patients with active disease and patients with inactive disease, the serum factor was found in 61% of the patients with active inflammatory disease and only in 14% of the patients with inactive disease. Furthermore this factor was also found in the serum of patients with an acute episode of uveitis, suggesting that it may be a useful marker for assessment of a localized inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649288      PMCID: PMC1542113     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Migration inhibitory activity in serum and cell supernatants in patients with Sezary syndrome.

Authors:  T Yoshida; R Edelson; S Cohen; I Green
Journal:  J Immunol       Date:  1975-03       Impact factor: 5.422

2.  Demonstration of delayed hypersensitivity to retrobulbar and thyroid tissues in human exophthalmos.

Authors:  P Mashieu; R Winand
Journal:  J Clin Endocrinol Metab       Date:  1972-06       Impact factor: 5.958

3.  Modification of the classification of the eye changes of Graves' disease.

Authors:  S C Werner
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

4.  Delayed hypersensitivity in Graves' disease and exophthalmos: identification of thyroglobulin in normal human orbital muscle.

Authors:  B R Mullin; R E Levinson; A Friedman; D E Henson; R J Winand; L D Kohn
Journal:  Endocrinology       Date:  1977-02       Impact factor: 4.736

5.  Molecular cloning and expression of hybridoma growth factor in Escherichia coli.

Authors:  J P Brakenhoff; E R de Groot; R F Evers; H Pannekoek; L A Aarden
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

6.  The influence of high molecular weight sodium hyaluronate (Healon) on the production of migration inhibitory factor.

Authors:  R van der Gaag; L Broersma; L Koornneef
Journal:  Curr Eye Res       Date:  1987-12       Impact factor: 2.424

7.  The pathogenesis of Graves' ophthalmopathy.

Authors:  P Kendall-Taylor
Journal:  Clin Endocrinol Metab       Date:  1985-05

8.  Detection of macrophage migration inhibitory factor by monoclonal antibody in Sézary syndrome.

Authors:  C Neumann; R Schlegel; F Steckel; C Sorg
Journal:  J Invest Dermatol       Date:  1987-06       Impact factor: 8.551

9.  Studies on human migration inhibitory factor: characterization of three molecular species.

Authors:  W Y Weiser; D K Greineder; H G Remold; J R David
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

10.  Serum macrophage migration inhibition activity in patients with leprosy.

Authors:  T H Rea; T Yoshida
Journal:  J Invest Dermatol       Date:  1982-11       Impact factor: 8.551

View more
  4 in total

1.  The peripheral blood compartment in patients with Graves' disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes.

Authors:  K Van der Weerd; P M Van Hagen; B Schrijver; D J Kwekkeboom; W W De Herder; M R J Ten Broek; P T E Postema; J J M Van Dongen; F J T Staal; W A Dik
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

2.  HLA-DR4 associated response to corticosteroids in Graves' ophthalmopathy patients.

Authors:  R van der Gaag; W M Wiersinga; L Koornneef; M P Mourits; M F Prummel; A Berghout; R R de Vries; G M Schreuder; J D'Amaro
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

3.  Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.

Authors:  M F Prummel; W M Wiersinga; R Van der Gaag; M P Mourits; L Koornneef
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

4.  A macrophage migration inhibitory factor is expressed in the differentiating cells of the eye lens.

Authors:  G J Wistow; M P Shaughnessy; D C Lee; J Hodin; P S Zelenka
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.